AAGH · America Great Health
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.”View the 10-Q filed Aug 6, 2026
2 customers — 22% of revenue (nine months ended March 31, 2026)
“For the nine months ended March 31, 2026, two major customers accounted for approximately 22% each of our total revenue during the period.”
One customer — 22% of revenue (nine months ended March 31, 2026)
“For the nine months ended March 31, 2026, two major customers accounted for approximately 22% each of our total revenue during the period.”
One customer — 13% of revenue (three months ended March 31, 2026)
“For the three months ended March 31, 2026, three major customers accounted for approximately 13%, 10% and 10% respectively of our total revenue during the period.”
2 customers — 10% of revenue (three months ended March 31, 2026)
“For the three months ended March 31, 2026, three major customers accounted for approximately 13%, 10% and 10% respectively of our total revenue during the period.”
One customer — 11% of revenue (nine months ended March 31, 2025)
“For the nine months ended March 31, 2025, only one major customer accounted for approximately 11% of our total revenue during the period.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AAGH
this stock
America Great Health
|
$4.24M | +200.0% | +32.9% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +13.9% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.83B | +2.3% | +20.8% | 19.2 | 2.5% |
|
ARGX
Argenx SE
|
$60.93B | +18.4% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$59.64B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AAGH | +50.0% | +200.0% | +0.0% | +0.0% | +200.0% |
| SPY | -1.1% | -1.8% | +14.8% | -1.7% | +10.6% |
| vs SPY | +51.1% | +201.8% | -14.8% | +1.7% | +189.4% |